Melatonin and Nitrones As Potential Therapeutic Agents for Stroke.

Abstract

Stroke is a disease of aging affecting millions of people worldwide, and recombinant tissue-type plasminogen activator (r-tPA) is the only treatment approved. However, r-tPA has a low therapeutic window and secondary effects which limit its beneficial outcome, urging thus the search for new more efficient therapies. Among them, neuroprotection based on melatonin or nitrones, as free radical traps, have arisen as drug candidates due to their strong antioxidant power. In this Perspective article, an update on the specific results of the melatonin and several new nitrones are presented.

• Authors: Alejandro Romero, Eva Ramos, Paloma Patiño, Maria J Oset-Gasque, Francisco López-Muñoz, José Marco-Contelles, María I Ayuso, Alberto Alcázar
• Journal: Frontiers in aging neuroscience (Front Aging Neurosci) Vol. 8 Pg. 281 ( 2016) ISSN: 1663-4365 [Print] Switzerland
• PMID: 27932976 (Publication Type: Journal Article)